182.09 USD
+0.15 (+0.08%)
182 USD
-0.09 (-0.05%)
Taking everything into account, BIIB scores 6 out of 10 in our fundamental rating. BIIB was compared to 533 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making BIIB a very profitable company, without any liquidiy or solvency issues. BIIB is valued quite cheap, but it does not seem to be growing. These ratings could make BIIB a good candidate for value investing.
1. Profitability
1.1 Basic Checks
BIIB had positive earnings in the past year.
In the past year BIIB had a positive cash flow from operations.
BIIB had positive earnings in each of the past 5 years.
In the past 5 years BIIB always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 5.51%, BIIB belongs to the top of the industry, outperforming 92.12% of the companies in the same industry.
BIIB has a Return On Equity of 8.84%. This is amongst the best in the industry. BIIB outperforms 93.06% of its industry peers.
BIIB has a better Return On Invested Capital (9.70%) than 94.56% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BIIB is significantly below the industry average of 18.83%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROIC | 9.7% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
BIIB has a Profit Margin of 15.98%. This is amongst the best in the industry. BIIB outperforms 93.25% of its industry peers.
BIIB's Profit Margin has declined in the last couple of years.
The Operating Margin of BIIB (28.50%) is better than 96.62% of its industry peers.
BIIB's Operating Margin has declined in the last couple of years.
With an excellent Gross Margin value of 75.24%, BIIB belongs to the best of the industry, outperforming 83.30% of the companies in the same industry.
BIIB's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
BIIB has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
BIIB has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BIIB has less shares outstanding
Compared to 1 year ago, BIIB has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 3.34 indicates that BIIB is not in any danger for bankruptcy at the moment.
BIIB has a better Altman-Z score (3.34) than 71.11% of its industry peers.
The Debt to FCF ratio of BIIB is 2.78, which is a good value as it means it would take BIIB, 2.78 years of fcf income to pay off all of its debts.
BIIB has a better Debt to FCF ratio (2.78) than 92.87% of its industry peers.
BIIB has a Debt/Equity ratio of 0.35. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of BIIB (0.35) is worse than 69.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 3.34 |
ROIC/WACC1.18
WACC8.22%
2.3 Liquidity
BIIB has a Current Ratio of 2.72. This indicates that BIIB is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.72, BIIB is doing worse than 67.17% of the companies in the same industry.
BIIB has a Quick Ratio of 2.04. This indicates that BIIB is financially healthy and has no problem in meeting its short term obligations.
BIIB has a worse Quick ratio (2.04) than 73.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 2.51% over the past year.
Measured over the past years, BIIB shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -13.31% on average per year.
The Revenue has been growing slightly by 4.77% in the past year.
Measured over the past years, BIIB shows a decrease in Revenue. The Revenue has been decreasing by -7.62% on average per year.
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
3.2 Future
Based on estimates for the next years, BIIB will show a small growth in Earnings Per Share. The EPS will grow by 0.52% on average per year.
Based on estimates for the next years, BIIB will show a decrease in Revenue. The Revenue will decrease by -0.65% on average per year.
EPS Next Y-5.79%
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%
EPS Next 5Y0.52%
Revenue Next Year1.35%
Revenue Next 2Y-1.88%
Revenue Next 3Y-1.34%
Revenue Next 5Y-0.65%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 10.88 indicates a reasonable valuation of BIIB.
97.19% of the companies in the same industry are more expensive than BIIB, based on the Price/Earnings ratio.
BIIB is valuated cheaply when we compare the Price/Earnings ratio to 26.31, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 11.66 indicates a reasonable valuation of BIIB.
Based on the Price/Forward Earnings ratio, BIIB is valued cheaper than 97.75% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of BIIB to the average of the S&P500 Index (36.59), we can say BIIB is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.88 | ||
| Fwd PE | 11.66 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BIIB is valued cheaper than 97.75% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BIIB indicates a rather cheap valuation: BIIB is cheaper than 98.12% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.8 | ||
| EV/EBITDA | 7.96 |
4.3 Compensation for Growth
BIIB has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%
5. Dividend
5.1 Amount
BIIB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
182.09
+0.15 (+0.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners92.49%
Inst Owner Change2.69%
Ins Owners0.14%
Ins Owner Change3.81%
Market Cap26.70B
Revenue(TTM)10.07B
Net Income(TTM)1.61B
Analysts73.81
Price Target179.46 (-1.44%)
Short Float %3.86%
Short Ratio3.21
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.2%
Min EPS beat(2)21.48%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)14.8%
EPS beat(12)12
Avg EPS beat(12)12.19%
EPS beat(16)14
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)8.93%
Min Revenue beat(2)6.23%
Max Revenue beat(2)11.62%
Revenue beat(4)4
Avg Revenue beat(4)6.16%
Min Revenue beat(4)0.11%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)2.33%
Revenue beat(16)11
Avg Revenue beat(16)2%
PT rev (1m)3.62%
PT rev (3m)4.42%
EPS NQ rev (1m)-54.11%
EPS NQ rev (3m)-54.55%
EPS NY rev (1m)-3.62%
EPS NY rev (3m)-4.16%
Revenue NQ rev (1m)-2.3%
Revenue NQ rev (3m)-2.13%
Revenue NY rev (1m)0.92%
Revenue NY rev (3m)0.95%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.88 | ||
| Fwd PE | 11.66 | ||
| P/S | 2.65 | ||
| P/FCF | 11.8 | ||
| P/OCF | 10.88 | ||
| P/B | 1.47 | ||
| P/tB | 11.19 | ||
| EV/EBITDA | 7.96 |
EPS(TTM)16.74
EY9.19%
EPS(NY)15.61
Fwd EY8.57%
FCF(TTM)15.43
FCFY8.47%
OCF(TTM)16.74
OCFY9.19%
SpS68.66
BVpS124.19
TBVpS16.27
PEG (NY)N/A
PEG (5Y)N/A
Graham Number216.28
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROCE | 11.07% | ||
| ROIC | 9.7% | ||
| ROICexc | 11.44% | ||
| ROICexgc | 40.96% | ||
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% | ||
| FCFM | 22.48% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.15%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Debt/EBITDA | 1.73 | ||
| Cap/Depr | 25.04% | ||
| Cap/Sales | 1.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 67.56% | ||
| Profit Quality | 140.63% | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 | ||
| Altman-Z | 3.34 |
F-Score5
WACC8.22%
ROIC/WACC1.18
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
EPS Next Y-5.79%
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%
EPS Next 5Y0.52%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
Revenue Next Year1.35%
Revenue Next 2Y-1.88%
Revenue Next 3Y-1.34%
Revenue Next 5Y-0.65%
EBIT growth 1Y15.15%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year7.73%
EBIT Next 3Y2.84%
EBIT Next 5Y1.64%
FCF growth 1Y120.5%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y80.46%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%
BIOGEN INC / BIIB FAQ
Can you provide the ChartMill fundamental rating for BIOGEN INC?
ChartMill assigns a fundamental rating of 6 / 10 to BIIB.
What is the valuation status for BIIB stock?
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (BIIB). This can be considered as Undervalued.
How profitable is BIOGEN INC (BIIB) stock?
BIOGEN INC (BIIB) has a profitability rating of 7 / 10.
Can you provide the expected EPS growth for BIIB stock?
The Earnings per Share (EPS) of BIOGEN INC (BIIB) is expected to decline by -5.79% in the next year.